Journal article · 2025 · Open access

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

Rana R. McKay, Sumanta Monty Pal, Wanling Xie, David Henry Aggen, Laurence K. Albiges, Andrea Borghese Apolo, Michael B. Atkins, Rick Bangs, Kathryn Eby Beckermann, Joaquim Bellmunt B, Stephanie A Berg, Mehmet Asım Bilen and 42 more

CA A Cancer Journal for Clinicians, 76(1), e70052 · Published 13 December 2025 · DOI 10.3322/caac.70052

Open PDFView at the publisherCite this paper

In brief

“Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers” is a 2025 journal article by Rana R. McKay and 53 co-authors, published in CA A Cancer Journal for Clinicians. OpenAlex counts 14 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at CA A Cancer Journal for Clinicians.

Citations
14
Most cited in
2026 (13)
Field-weighted impact
4.05
References
28
Authors
54

Abstract

The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence-based expert consensus recommendations for optimal management. A multidisciplinary panel of 51 experts participated in a modified Delphi process addressing questions developed through iterative consensus-building covering RCC and UTC management. Voting occurred before and after the conference, and analyses focused on postmeeting responses. Consensus was defined as ≥75% agreement, with strong consensus as >90%. Strong consensus was found on the use of adjuvant pembrolizumab for higher risk RCC (pathologic T2 [pT2], grade 4; pT3-pT4, any grade; pTXN1; or fully resected metastatic disease) and on neoadjuvant therapy before cystectomy for localized UTC. There was strong consensus on the use of enfortumab vedotin plus pembrolizumab as frontline therapy for metastatic UTC and the use of platinum-based chemotherapy postprogression in biomarker-negative UTC. For RCC, there was consensus on the role of single-agent vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy after progression on frontline immune checkpoint inhibitor/vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy or dual immune checkpoint inhibitor therapy. However, there was a lack of consensus on other critical areas in the management of RCC and UTC. The 2025 Advanced Urologic Cancer Consensus Conference provides evidence-informed guidance for complex clinical scenarios while identifying critical research priorities. The group recognizes that the lack of consensus across multiple areas highlights the need for improved patient selection and prospective studies enabling optimal combination and sequencing approaches. This iterative annual process will address evolving treatment paradigms to optimize outcomes.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

McKay, R. R., Pal, S. M., Xie, W., Aggen, D. H., Albiges, L. K., Apolo, A. B., Atkins, M. B., Bangs, R., Beckermann, K. E., B, J. B., Berg, S. A., Bilen, M. A., Braun, D. A., Carlo, M. I., Efstathiou, J. A., Galsky, M. D., Grivas, P. D., Gupta, S., Haas, N. B., . . . Choueiri, T. K. (2025). Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA A Cancer Journal for Clinicians, 76(1), e70052. https://doi.org/10.3322/caac.70052

MLA 9

McKay, Rana R., et al. “Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.” CA A Cancer Journal for Clinicians, vol. 76, no. 1, 2025, p. e70052. https://doi.org/10.3322/caac.70052.

Chicago

McKay, Rana R., Sumanta Monty Pal, Wanling Xie, David Henry Aggen, Laurence K. Albiges, Andrea Borghese Apolo, Michael B. Atkins, et al. 2025. “Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.” CA A Cancer Journal for Clinicians 76 (1): e70052. https://doi.org/10.3322/caac.70052.

Harvard

McKay, R. R. et al. (2025) ‘Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers’, CA A Cancer Journal for Clinicians, 76(1), p. e70052. doi:10.3322/caac.70052.

IEEE

R. R. McKay et al., “Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers,” CA A Cancer Journal for Clinicians, vol. 76, no. 1, p. e70052, 2025, doi: 10.3322/caac.70052.

BibTeX

@article{mckay2025advanced,
  title     = {{Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers}},
  author    = {McKay, Rana R. and Pal, Sumanta Monty and Xie, Wanling and Aggen, David Henry and Albiges, Laurence K. and Apolo, Andrea Borghese and Atkins, Michael B. and Bangs, Rick and Beckermann, Kathryn Eby and B, Joaquim Bellmunt and Berg, Stephanie A and Bilen, Mehmet Asım and Braun, David A. and Carlo, Maria Isabel and Efstathiou, Jason Alexander and Galsky, Matthew D. and Grivas, Petros D. and Gupta, Shilpa and Haas, Naomi Balzer and Hakimi, A. Ari and Hammers, Hans J. and Heng, Daniel Yick Chin and Hirsch, Michelle S. and Iyer, Gopa and Jonasch, Eric W. and Koshkin, Vadim S. and Kryvenko, Oleksandr N. and Lewis, Bryan and Li, Roger and Matin, Surena F. and others},
  journal   = {CA A Cancer Journal for Clinicians},
  year      = {2025},
  volume    = {76},
  number    = {1},
  pages     = {e70052},
  doi       = {10.3322/caac.70052},
  url       = {https://doi.org/10.3322/caac.70052}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment

  • renal cell carcinoma
  • urinary tract cancer
  • bladder cancer
  • pembrolizumab
  • adjuvant immunotherapy
  • neoadjuvant therapy
  • enfortumab vedotin
  • platinum-based chemotherapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

McKay, R. R., Pal, S. M., Xie, W., Aggen, D. H., Albiges, L. K., Apolo, A. B., Atkins, M. B., Bangs, R., Beckermann, K. E., B, J. B., Berg, S. A., Bilen, M. A., Braun, D. A., Carlo, M. I., Efstathiou, J. A., Galsky, M. D., Grivas, P. D., Gupta, S., Haas, N. B., . . . Choueiri, T. K. (2025). Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA A Cancer Journal for Clinicians, 76(1), e70052. https://doi.org/10.3322/caac.70052

How many times has this paper been cited?

14 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at CA A Cancer Journal for Clinicians: sign in and open the PDF from this page.

Who wrote this paper?

Rana R. McKay, Sumanta Monty Pal, Wanling Xie, David Henry Aggen, Laurence K. Albiges, Andrea Borghese Apolo, Michael B. Atkins, Rick Bangs, Kathryn Eby Beckermann, Joaquim Bellmunt B, Stephanie A Berg, Mehmet Asım Bilen and 42 more.

What is the DOI of this paper?

10.3322/caac.70052, permanently at https://doi.org/10.3322/caac.70052. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.